Your Health, We Care
The efficacy of Ivosidenib in the treatment of AML has been further validated. Companies such as R&D manufacturer Agios continue to promote the clinical development and commercialization of Ivosidenib to meet the treatment needs of more patients.
As a monotherapy for locally advanced or metastatic cholangiocarcinoma patients with IDH1 R132 mutations, Ivosidenib has also achieved positive results.
Is the Lao Lucius version of Ivosidenib available on the market?Ivosidenib, an i···【more】
Release date：2024-11-28Recommended：100
